Ring Carbon Is Shared By Three Of The Cyclos Patents (Class 546/75)
-
Patent number: 10443201Abstract: A soil compactor is described. The soil compactor includes at least two vibrating compacting rollers rotatable about a respective roller axis of rotation. The soil compactor further includes a vibration excitation arrangement assigned to each vibrating compacting roller of the at least two vibrating compacting rollers for generating a vibrating movement of the at least two vibrating compacting rollers. The soil compactor also includes a sensor arrangement assigned to the soil compactor for providing a feedback signal indicative of sound or a structural vibration of the soil compactor. The soil compactor yet further includes a control unit receiving the feedback signal for controlling at least one vibration excitation arrangement, based on the feedback signal, such as to act on a phase offset of the vibrating movements of the at least two vibrating compacting rollers with respect to one another.Type: GrantFiled: May 10, 2017Date of Patent: October 15, 2019Assignee: Hamm AGInventors: Klaus Meindl, Hans-Peter Patzner, Axel Römer
-
Publication number: 20150048323Abstract: A condensed-cyclic compound and an organic light-emitting device including the same, the compound being represented by Formula 1, below:Type: ApplicationFiled: April 22, 2014Publication date: February 19, 2015Applicant: SAMSUNG DISPLAY CO., LTD.Inventors: Soo-Yon KIM, Seok-Hwan HWANG, Young-Kook KIM, Hye-Jin JUNG, Jun-Ha PARK, Eun-Young LEE, Jong-Woo KIM, Jin-O LIM, Sang-Hyun HAN, Kwang-Hyun KIM, Eun-Jae JEONG
-
Publication number: 20140239288Abstract: The invention relates to substituted ullazine and analogs of ullazine as sensitizers for dye-sensitized solar cells (DSSCs) and other photoelectrochemical and/or optoelectronic devices. The sensitizers may comprise donor substituents and/or acceptor substituents, besides an anchoring group suitable for attaching the sensitizer on a semiconductor surface. DSSCs based on this type of sensitizers exhibit high power conversion efficiencies.Type: ApplicationFiled: October 18, 2011Publication date: August 28, 2014Applicant: Ecole Polytechnique Féderale de Lausanne (EPFL)Inventors: Jared Delcamp, Michael Graetzel, Mohammad Khaja Nazeeruddin
-
Publication number: 20140155609Abstract: The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders.Type: ApplicationFiled: November 24, 2010Publication date: June 5, 2014Applicant: Dong-A ST Co., Ltd.Inventors: Miwon Son, Tae Ho Lee, Sang Zin Choi, Nam Joon Baek, Kang Ro Lee, Ki Hyun Kim, Soon Hoe Kim
-
Patent number: 8637658Abstract: Bis-diazo, triaryl and aryldiazo-N-arylphenazonium quencher moieties, substituted with electron-withdrawing and electron-donating substituents which induce polarity in the delocalized aryl/diazo ring systems, are useful as labels when attached to biomolecules such as polynucleotides, nucleosides, nucleotides and polypeptides. The quencher moieties are non-fluorescent and accept energy transfer from fluorescent reporter labels by any energy-transfer mechanism, such as FRET. Fluorescence quencher compositions are useful in preparing quencher labeled biomolecules for various molecular biology assays based on fluorescence detection.Type: GrantFiled: September 27, 2012Date of Patent: January 28, 2014Assignee: Applied Biosystems, LLCInventors: Gregory J. Ewing, Khairuzzaman Bashar Mullah, Ronald Graham
-
Patent number: 8628863Abstract: Provided is an organic light-emitting device having an optical output with high luminance and high color purity with extremely high efficiency. The organic light-emitting device includes an organic layer between the anode and the cathode, in which one of the anode and the cathode is a transparent electrode or a semi-transparent electrode and at least one layer of the organic layer contains at least one kind of indenopyrene compound having a specific structure.Type: GrantFiled: November 6, 2009Date of Patent: January 14, 2014Assignee: Canon Kabushiki KaishaInventors: Takeshi Sekiguchi, Hiroshi Tanabe, Hiroki Ohrui, Masanori Seki
-
Patent number: 8592424Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy is disclosed.Type: GrantFiled: June 29, 2009Date of Patent: November 26, 2013Assignee: Afgin Pharma LLCInventor: Ronald Aung-Din
-
Publication number: 20130296571Abstract: The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders.Type: ApplicationFiled: November 24, 2010Publication date: November 7, 2013Applicant: Dong-A ST Co., Ltd.Inventors: Miwon Son, Tae Ho Lee, Sang Zin Choi, Nam Joon Baek, Kang Ro Lee, Ki Hyun Kim, Soon Hoe Kim
-
Patent number: 8563727Abstract: The present invention provides (+)-morphinanium N-oxide compounds or pharmaceutically acceptable salts thereof. The invention also provides processes for producing (+)-morphinanium N-oxides or pharmaceutically acceptable salts thereof from the corresponding tertiary N-substituted (+)-morphinan compound or pharmaceutically acceptable salt thereof.Type: GrantFiled: February 23, 2010Date of Patent: October 22, 2013Assignee: Mallinckrodt LLCInventors: Gary L. Cantrell, Peter X. Wang, Bobby N. Trawick, Christopher W. Grote, David W. Berberich, Hang Sun, Subo Liao
-
Publication number: 20130261146Abstract: A pharmaceutical composition for stimulating nitric oxide production in mammalian cells, the pharmaceutical composition including at least one compound selected from a group consisting of: 2,3-dihydroxypropyl oleate; bis(m-phenoxyphenyl) ether; 6-acetyl-5,6,6a,7-tetrahydro-4H-dibezo(de,g)quinoline; and (+)-N-(p-(2-methylbutoxy)benzylidene)-4-(2-methylbutyl)aniline.Type: ApplicationFiled: December 9, 2010Publication date: October 3, 2013Applicant: The Research Foundation of State University of New YorkInventors: George B. Stefano, Wei Zhu, Kirk Mantione, Richard M. Kream
-
Publication number: 20130209362Abstract: The invention features 2-alkoxy-11-hydroxyaporphine derivatives that selectively bind D2high receptors. The compounds are useful for imaging D2high receptors and for the treatment of diseases, such as Parkinson's disease, sexual dysfunction, and depressive disorders.Type: ApplicationFiled: April 14, 2011Publication date: August 15, 2013Applicant: The McLean Hospital CorporationInventors: John L. Neumeyer, Yu-Gui Si, Anna W. Sromek
-
Publication number: 20130203762Abstract: This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for reducing udder engorgement and/or the reduction of pain after drying off and/or of increasing welfare, and/or of reducing milk leakage in ruminants as well as for preventing new mammary microbial infections, secondary infection, or co-infections in ruminants and mastitis.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicant: CEVA SANTE ANIMALEInventor: CEVA SANTE ANIMALE
-
Patent number: 8431591Abstract: The invention features derivatives of R(?)-2-methoxy-11-hydroxyaporphines and methods of treating Parkinson's disease and sexual dysfunction therewith.Type: GrantFiled: July 10, 2008Date of Patent: April 30, 2013Assignee: The McLean Hospital CorporationInventors: John L. Neumeyer, Yu-Gui Si
-
Publication number: 20120326133Abstract: A compound represented by Formula 1 below and an organic light-emitting device including an organic layer containing the compound of Formula 1: wherein R1 to R4, X and Y, a and b, and m and n are defined as in the specification.Type: ApplicationFiled: December 2, 2011Publication date: December 27, 2012Applicant: SAMSUNG MOBILE DISPLAY CO., LTD.Inventors: Myeong-Suk Kim, Dong-Woo Shin, Sung-Soo Bae, Ji-Hye Shim, Dae-Yup Shin, Byoung-Ki Choi
-
Publication number: 20120226043Abstract: The present invention provides methods of N-demethylating, N-methylated heterocycles and N-methyl, N-oxide heterocycles using a transition metal with an oxidation state of zero, ferrocene or substituted derivatives thereof, or Cr3+. N-demethylated heterocycles prepared by the methods of the present invention are also provided.Type: ApplicationFiled: September 16, 2010Publication date: September 6, 2012Applicant: MONASH UNIVERSITYInventors: Peter John Scammells, Gaik Orbell
-
Patent number: 8202995Abstract: The present invention discloses novel pharmaceutically acceptable salts of aporphine compounds and carboxyl-group containing agents. Also, the present invention discloses methods for preparing the pharmaceutically acceptable salts. These pharmaceutically acceptable salts are suitable for use in treating and/or preventing hyperglycemic disease and/or several oxidative stress related diseases.Type: GrantFiled: June 19, 2009Date of Patent: June 19, 2012Assignee: Standard Chem. & Pharm. Co., Ltd.Inventors: Chin-Tsai Fan, Cheng-Shun Lai, Mei-Jung Lin
-
Patent number: 8101759Abstract: It is an object to provide a new compound which is suitable for a material of an electron-transporting layer of a light-emitting element. In particular, it is an object to provide a compound which can be used for forming a light-emitting element capable of emitting light at a low drive voltage. An acenaphthopyridine derivative represented by the following general formula (G1) is provided. In the formula, Het represents a pyridyl group or a quinolyl group.Type: GrantFiled: March 24, 2009Date of Patent: January 24, 2012Assignee: Semiconductor Energy laboratory Co., Ltd.Inventors: Takako Takasu, Ryoji Nomura, Satoko Shitagaki, Satoshi Seo
-
Patent number: 8093260Abstract: The present invention discloses novel aporphine derivatives. Also, the present invention discloses that these novel aporphine derivatives can be used for treating oxidative stress induced diseases such as cardiovascular disease, diabetes, aging, Alzheimer's disease, kidney disease, cancer or brain ischemic disease etc.Type: GrantFiled: June 19, 2009Date of Patent: January 10, 2012Assignee: Standard Chem. & Pharm. Co., Ltd.Inventors: Chin-Tsai Fan, Cheng-Shun Lai, Mei-Jung Lin
-
Patent number: 8063060Abstract: The invention features derivatives of R(?)-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.Type: GrantFiled: December 4, 2009Date of Patent: November 22, 2011Assignee: The McLean Hospital CorporationInventors: John L. Neumeyer, Ross J. Baldessarini
-
Patent number: 8034944Abstract: There are provided a novel benzofluoranthene compound and an organic light-emitting device which uses the benzofluoranthene compound, gives a blue emission hue with extremely good purity, and has an optical output with a high efficiency, a high luminance, and a long life. Specifically, there are provided a benzofluoranthene compound represented by the general formula shown below and an organic light-emitting device including a pair of electrodes including an anode and a cathode one of which is a transparent or translucent electrode material, and an organic compound layer disposed between the pair of electrodes and including a material for an organic light-emitting device containing the benzofluoranthene compound. In the general formula (1), one of X1, X2, X3, X4, X5, and X6 represents a substituted or unsubstituted fused heterocyclic group having four or less rings, and the others of X1, X2, X3, X4, X5, and X6 each represent a hydrogen atom.Type: GrantFiled: December 12, 2007Date of Patent: October 11, 2011Assignee: Canon Kabushiki KaishaInventors: Hiroki Ohrui, Akihito Saitoh, Chika Negishi, Hironobu Iwawaki, Masanori Muratsubaki, Hiroyuki Tomono, Tetsuya Kosuge, Akihiro Senoo
-
Publication number: 20110245493Abstract: The present invention relates to the delivery of drug amines through an inhalation route. Specifically, it relates to aerosols containing drug amines that are used in inhalation therapy. In one aspect of the present invention, a method of delivering an amine drug in an aerosol form is provided. The method comprises: a) heating a coating, which includes an amine drug salt on a substrate contained in a device to a temperature sufficient to volatilize the amine drug from the coating, h) by said heating, forming an amine drug vapor, and c) during said heating, drawing air through said device, condensing said vapor to form aerosol particles containing less than 10% degradation products of the compound.Type: ApplicationFiled: April 1, 2011Publication date: October 6, 2011Applicant: ALEXZA PHARMACEUTICALS, INC.Inventors: Joshua D. RABINOWITZ, Alejandro C. Zaffaroni
-
Publication number: 20110204354Abstract: Provided is an organic light-emitting device having an optical output with high luminance and high color purity with extremely high efficiency. The organic light-emitting device includes an organic layer between the anode and the cathode, in which one of the anode and the cathode is a transparent electrode or a semi-transparent electrode and at least one layer of the organic layer contains at least one kind of indenopyrene compound having a specific structure.Type: ApplicationFiled: November 6, 2009Publication date: August 25, 2011Applicant: CANON KABUSHIKI KAISHAInventors: Takeshi Sekiguchi, Hiroshi Tanabe, Hiroki Ohrui, Masanori Seki
-
Publication number: 20110190307Abstract: The present invention provides zebrafish based methods for the identification of compounds potentially useful in the treatment of motor neuron degenerative diseases (MNDDs), compounds identified by these methods and compositions, methods and medicaments for treating MNDDs.Type: ApplicationFiled: June 25, 2009Publication date: August 4, 2011Inventors: Catherina G. Becker, Thomas Becker
-
Publication number: 20110178068Abstract: The invention provides a method of sustained delivery of a tertiary amine-containing parent drug comprising administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile quaternary ammonium salts of tertiary amine-containing parent drugs (or tertiary imine-containing parent drugs) that are derivatized through aldehyde-linked prodrug moieties that reduce the solubility of the prodrug compound at a reference pH as compared to the parent drug. The physical, chemical and solubility properties of these derivatives can be further modulated by the choice of counterion X?. In one embodiment, the present invention provides a prodrug compound of Formula I: where R1-R5 are defined in the written description of the invention.Type: ApplicationFiled: December 23, 2010Publication date: July 21, 2011Applicant: Alkermes, Inc.Inventors: Orn Almarsson, Laura Cook Blumberg, Julius F. Remenar
-
Publication number: 20110152220Abstract: The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.Type: ApplicationFiled: March 30, 2009Publication date: June 23, 2011Inventors: Gerard Karsenty, Patricia F. Ducy, Yuli Xie, Donald Landry, Vijay Kumar Yadav
-
Publication number: 20110111011Abstract: The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.Type: ApplicationFiled: June 11, 2010Publication date: May 12, 2011Inventors: Anthony John Giovinazzo, David Bruce Hedden, Marc L. de Somer, Nathan John Bryson
-
Patent number: 7820822Abstract: The present invention describes new types of metal complexes. Such compounds can be used as functional materials in a series of different types of applications which can be classified within the electronics industry in the widest sense. The inventive compounds are described by the formulae (1) and (4).Type: GrantFiled: September 28, 2004Date of Patent: October 26, 2010Assignee: Merck Patent GmbHInventors: Rocco Fortte, Philipp Stössel, Anja Gerhard, Horst Vestweber
-
Patent number: 7816406Abstract: The present invention provides quinolone analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing quinolone analogs, and methods of using the same.Type: GrantFiled: September 16, 2005Date of Patent: October 19, 2010Assignee: Cylene Pharmaceuticals, Inc.Inventors: Jeffrey P. Whitten, Fabrice Pierre, Collin Regan, Michael Schwaebe, Johnny Y. Nagasawa, Peter Chua
-
Publication number: 20100228032Abstract: There is provided an improved and convenient process for the synthesis of aporphines, such as apomorphine and apocodeine, by the rearrangement of the corresponding morphine or codeine derivatives. The use of a suitable water scavenger in an acid catalyzed rearrangement of the morphine derivatives unexpectedly results in a reaction temperature convenient for plant operation without sacrificing product. The method of the present invention also alleviates the cumbersome operations that were employed in the prior art to eliminate water from the reaction mixture at the elevated temperatures. This process is adaptable for the general preparation of other aporphines from the corresponding morphine congeners.Type: ApplicationFiled: March 21, 2007Publication date: September 9, 2010Inventor: Narayanasamy Gurusamy
-
Publication number: 20100216998Abstract: An improved method for producing apomorphine and derivatives thereof is provided. The method is a convenient ‘one-pot’ process, comprising the conversion of codeine into apomorphine without isolating the apocodeine intermediate. Use of water reactive scavengers, reagents that will react irreversibly with water, decreases side product formation and allows the use of milder reaction conditions. This one-pot synthesis of apomorphine from codeine provides a faster reaction with improved yields at temperatures lower as compared to conventional methods. The lower operating temperatures and less volatile reactants make the method particularly useful for large-scale manufacturing.Type: ApplicationFiled: September 2, 2008Publication date: August 26, 2010Applicant: MALLINCKRODT INC.Inventor: Narayanasamy Gurusamy
-
Patent number: 7741337Abstract: The present invention is directed to azonafide derivatives obtained by reacting azonafide with aldehydes, acyl halides, thioacyl halides, monoisocyanates, isothiocyanates, sulfonyl halides, monohalogenoalkanes, monohalogenoalkenes or monohalogenoalkynes, and are useful as active ingredients of pharmaceutical compositions for the prevention and treatment of cell proliferative disorders, in particular several forms of cancer.Type: GrantFiled: November 9, 2006Date of Patent: June 22, 2010Assignee: Unibioscreen S.A.Inventors: Eric Van Quaquebeke, Jérôme Tuti, Laurent Van den Hove, Robert Kiss, Francis Darro
-
Publication number: 20100127618Abstract: There is provided an organic light-emitting device having an optical output with a high efficiency, a high luminance, and a long life.Type: ApplicationFiled: May 16, 2008Publication date: May 27, 2010Applicant: CANON KABUSHIKI KAISHAInventors: Hiroki Ohrui, Akihito Saitoh, Chika Negishi, Hironobu Iwawaki, Masanori Muratsubaki, Shinjiro Okada
-
Publication number: 20100081651Abstract: The invention features derivatives of R(?)-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.Type: ApplicationFiled: December 4, 2009Publication date: April 1, 2010Applicant: The McLean Hospital CorporationInventors: John L. Neumeyer, Ross L. Baldessarini
-
Publication number: 20100040545Abstract: The present invention relates to methods of synthesising radiolabelled compounds, to the precursors useful in such methods and to the radiolabelled compounds obtainable by such methods. More particularly, the present invention relate to methods, precursors and radiolabelled compounds useful in Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) especially for imaging neuroreceptors with radiolabelled agonists.Type: ApplicationFiled: December 19, 2007Publication date: February 18, 2010Inventors: Erik Arstad, David Turton
-
Patent number: 7648995Abstract: The invention features derivatives of R(—)-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.Type: GrantFiled: April 13, 2005Date of Patent: January 19, 2010Assignee: The McLean Hospital CorporationInventors: John L. Neumeyer, Ross J. Baldessarini
-
Publication number: 20090318489Abstract: The present invention discloses novel aporphine derivatives. Also, the present invention discloses that these novel aporphine derivatives can be used for treating oxidative stress induced diseases such as cardiovascular disease, diabetes, aging, Alzheimer's disease, kidney disease, cancer or brain ischemic disease etc.Type: ApplicationFiled: June 19, 2009Publication date: December 24, 2009Applicant: Standard Chem. & Pharm. Co., Ltd.Inventors: Chin-Tsai Fan, Cheng-Shun Lai, Mei-Jung Lin
-
Publication number: 20090278118Abstract: There are provided a novel benzofluoranthene compound and an organic light-emitting device which uses the benzofluoranthene compound, gives a blue emission hue with extremely good purity, and has an optical output with a high efficiency, a high luminance, and a long life. Specifically, there are provided a benzofluoranthene compound represented by the general formula shown below and an organic light-emitting device including a pair of electrodes including an anode and a cathode one of which is a transparent or translucent electrode material, and an organic compound layer disposed between the pair of electrodes and including a material for an organic light-emitting device containing the benzofluoranthene compound. In the general formula (1), one of X1, X2, X3, X4, X5, and X6 represents a substituted or unsubstituted fused heterocyclic group having four or less rings, and the others of X1, X2, X3, X4, X5, and X6 each represent a hydrogen atom.Type: ApplicationFiled: December 12, 2007Publication date: November 12, 2009Applicant: CANON KABUSHIKI KAISHAInventors: Hiroki Ohrui, Akihito Saitoh, Chika Negishi, Hironobu Iwawaki, Masanori Muratsubaki, Hiroyuki Tomono, Tetsuya Kosuge, Akihiro Senoo
-
Publication number: 20090247753Abstract: It is an object to provide a new compound which is suitable for a material of an electron-transporting layer of a light-emitting element. In particular, it is an object to provide a compound which can be used for forming a light-emitting element capable of emitting light at a low drive voltage. An acenaphthopyridine derivative represented by the following general formula (G1) is provided. In the formula, Het represents a pyridyl group or a quinolyl group.Type: ApplicationFiled: March 24, 2009Publication date: October 1, 2009Inventors: Takako Takasu, Ryoji Nomura, Satoko Shitagaki, Satoshi Seo
-
Publication number: 20090203724Abstract: The solid state chemistry of 17?-N-[2,5-bis(trifluoromethyl)phenyl]carbamoyl-4-aza-5-?-androst-1-en-3-one of which the international nonproprietary name is Dutasteride (the active ingredient in products marketed as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost) and its process for preparing. The synthetic process comprises formation of the mixed anhydride, its subsequent reaction with 2,5-bis(trifluoromethyl)phenylamine in the presence of an appropriate Lewis catalyst and its isolation, purification and crystallization from acetonitrile/water.Type: ApplicationFiled: January 3, 2009Publication date: August 13, 2009Applicant: GADOR S.A.Inventors: Dora Graciela Tombari, Constanza Pia Mangone, Maria Beatriz Garcia, Adriana Vecchioli, Rafael Alberto Labriola
-
Patent number: 7408072Abstract: The present invention provides heteropolycyclic compounds represented by General Formulae (1) and (2): wherein R1 is a straight- or branched-chain C1-C10 alkyl group or the like; R2 and R3 are the same or different and are each a straight- or branched-chain C1-C10 alkyl group or the like; R4 and R5 are each a hydrogen atom; X is —OH or the like; X? is a straight- or branched-chain C1-C10 alkyl group or the like; and Z is —O— or the like. The heteropolycyclic compounds of the present invention have appropriate optical absorption wavelengths and fluorescence wavelengths and a high luminescence intensity, and can be advantageously used in various applications as colorants that have excellent performance in terms of heat resistance, light resistance, solubility, dispersibility in resist materials, solid luminescence, etc.Type: GrantFiled: February 10, 2005Date of Patent: August 5, 2008Assignee: Kochi UniversityInventors: Katsuhira Yoshida, Yousuke Ooyama
-
Patent number: 7354926Abstract: The invention concerns novel molecules derived from noraporphine, as well as cosmetic and dermopharmaceutical compositions containing one or several of said derivatives, alone or combined with a plant extract, in particular glaucium flavum, and particularly preparations for reducing pigmentation, with anti-ageing effect or for slimming.Type: GrantFiled: July 29, 2003Date of Patent: April 8, 2008Assignee: Sederma SASInventor: Karl Lintner
-
Patent number: 7332503Abstract: New aporphine derivatives are disclosed which have formula (I) and the physiologically acceptable salts thereof. Said derivatives may be used for the treatment of Parkinson's disease, hemicrania, restless legs syndrome (RLS), sexual dysfunction in men and women, hyperprolactemia and psychotic disorders, and/or evaluation of Parkinson's disease. Processes for the preparation of such derivatives are also disclosed.Type: GrantFiled: February 22, 2005Date of Patent: February 19, 2008Assignee: Axon Biochemicals B.V.Inventors: Hakan Wikstrom, Durk Dijkstra, Thomas Cremers, Per Erik Andren, Sandrine Marchais, Ulrik Jurva
-
Patent number: 7323566Abstract: A novel group of apomorphine derivatives are provided that are well suited as radioimaging agents upon incorporation of radionuclides. Through reaction of D ring sites, the less reactive sites of the apomorphine A ring is modified in ways previously unattainable.Type: GrantFiled: April 20, 2005Date of Patent: January 29, 2008Inventor: Crist N. Filer
-
Patent number: 7291429Abstract: Naphthalenetetracarboxylic acid diimide derivatives and an electrophotographic photoconductive material containing the naphthalenetetracarboxylic acid diimide derivatives. The naphthalenetetracarboxylic acid diimide derivatives have a structure represented by the following formula: in which, R1 and R2 are each independently selected from the group consisting of a substituted or non-substituted C1-C20 alkyl group; a substituted or non-substituted C1-C20 alkoxy group; a substituted or non-substituted C6-C30 aryl group; and a substituted or non-substituted C7-C30 aralkyl group; and halogen. The electrophotographic photoconductive material includes the naphthalenetetracarboxylic acid diimide derivatives as an electron transferring material.Type: GrantFiled: June 3, 2004Date of Patent: November 6, 2007Assignee: Samsung Electronics Co., Ltd.Inventors: Beom-jun Kim, Saburo Yokota, Kyung-yol Yon, Hwan-koo Lee, Seung-ju Kim
-
Patent number: 7262298Abstract: 4-Hydroxybenzomorphans containing carboxamide or thiocarboxamide at the 3-position are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.Type: GrantFiled: November 3, 2005Date of Patent: August 28, 2007Assignee: Rensselaer Polytechnic InstituteInventor: Mark P. Wentland
-
Patent number: 7238705Abstract: New aporphine derivatives are disclosed which have formula (I) and the physiologically acceptable salts thereof. Said derivatives may be used for the treatment of Parkinson's disease, hemicrania, restless legs syndrome (RLS), sexual dysfunction in men and women, hyperprolactemia and psychotic disorders, and/or evaluation of Parkinson's disease. Processes for the preparation of such derivatives are also disclosed.Type: GrantFiled: July 20, 2001Date of Patent: July 3, 2007Assignee: Axon Biochemicals B.V.Inventors: Hakan Wikstrom, Durk Dijkstra, Thomas Cremers, Per Erik Andren, Sandrine Marchais, Ulrik Jurva
-
Patent number: 7220754Abstract: Mono-ester and asymmetrically substituted diesters of dihydrexidine, dinapsoline and A-86929 and substituted derivatives thereof are described. The novel ester/diester derivatives exhibit improved pharmacokinetic characteristics relative to their unesterified parent compounds and can be formulated into pharmaceutical compositions useful for the treatment of a wide variety of dopamine related disorders.Type: GrantFiled: February 14, 2003Date of Patent: May 22, 2007Assignee: DarPharma, Inc.Inventors: Durk Dijkstra, Hakan Wikstrom
-
Patent number: 7060829Abstract: Disclosed are novel colorant compounds which contain one or more ethylenically-unsaturated (vinyl), photopolymerizable radicals which may be copolymewrized (or cured) with ethylenically-unsaturated monomers to produce colored compositions such as colored acrylic coatings and polymers, e.g., coatings and polymers produced from acrylate and methacrylate esters, colored polystyrenes, and similar colored polymeric materials derived from other ethylenically-unsaturated monomers. The present invention also pertains to processes for the preparation of certain of the photopolymerizable colorant compounds.Type: GrantFiled: September 3, 2003Date of Patent: June 13, 2006Assignee: Eastman Chemical CompanyInventors: Michael John Cyr, Max Allen Weaver, Gerry Foust Rhodes, Jason Clay Pearson, Phillip Michael Cook
-
Patent number: 7057044Abstract: The invention provides aporphine and oxoaporphine compounds that have endothelial nitric oxide synthase (eNOS) maintaining or enhancing activities and may be used to manufacture a medicaments for preventing or treating ischemic diseases in human and mammal, and the ischemic diseases may include ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephlopathy, ischemic cardiac disease or ischemic enteropathy etc.Type: GrantFiled: April 2, 2004Date of Patent: June 6, 2006Assignee: Lotus Pharmaceutical Co., Ltd.Inventors: MingJai Su, ShoeiSheng Lee
-
Patent number: 7030244Abstract: Disclosed are novel colorant compounds which contain one or more ethylenically-unsaturated (vinyl), photopolymerizable radicals which may be copolymewrized (or cured) with ethylenically-unsaturated monomers to produce colored compositions such as colored acrylic coatings and polymers, e.g., coatings and polymers produced from acrylate and methacrylate esters, colored polystyrenes, and similar colored polymeric materials derived from other ethylenically-unsaturated monomers. The present invention also pertains to processes for the preparation of certain of the photopolymerizable colorant compounds.Type: GrantFiled: September 3, 2003Date of Patent: April 18, 2006Assignee: Eastman Chemical CompanyInventors: Michael John Cyr, Max Allen Weaver, Gerry Foust Rhodes, Jason Clay Pearson, Phillip Michael Cook